New hope for young bone cancer patients: immune drug tested in relapse

NCT ID NCT03006848

First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 26 times

Summary

This study tested a drug called avelumab in 19 children and young adults (ages 12 to 49) whose osteosarcoma (a type of bone cancer) had come back or was not responding to standard treatments. The goal was to see if avelumab could shrink tumors or stop the cancer from growing for at least 16 weeks. Researchers also monitored side effects and quality of life. The drug works by helping the immune system attack cancer cells.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OSTEOSARCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Children's Hospital Los Angeles

    Los Angeles, California, 90027, United States

  • Memorial Sloan-Kettering Cancer Center

    New York, New York, 10065, United States

  • St Jude Children's Research Hospital

    Memphis, Tennessee, 38105, United States

  • Texas Children's Cancer Center

    Houston, Texas, 77030, United States

Conditions

Explore the condition pages connected to this study.